Royalty Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Royalty Pharma has a total shareholder equity of $10.3B and total debt of $7.6B, which brings its debt-to-equity ratio to 73.6%. Its total assets and total liabilities are $18.2B and $7.9B respectively. Royalty Pharma's EBIT is $1.3B making its interest coverage ratio 7.3. It has cash and short-term investments of $987.2M.
Key information
73.6%
Debt to equity ratio
US$7.61b
Debt
| Interest coverage ratio | 7.3x |
| Cash | US$987.23m |
| Equity | US$10.34b |
| Total liabilities | US$7.88b |
| Total assets | US$18.22b |
Recent financial health updates
We Think Royalty Pharma (NASDAQ:RPRX) Can Stay On Top Of Its Debt
Dec 05
Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt
Aug 28Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Recent updates
Royalty Pharma: Delivering Growth With A Positive Story Ahead
Feb 13Subdued Growth No Barrier To Royalty Pharma plc (NASDAQ:RPRX) With Shares Advancing 25%
Jan 29Royalty Pharma: Key Strategic Updates To Be Priced In
Jan 15Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.22
Jan 13We Think Royalty Pharma (NASDAQ:RPRX) Can Stay On Top Of Its Debt
Dec 05Solid Earnings May Not Tell The Whole Story For Royalty Pharma (NASDAQ:RPRX)
Nov 13Royalty Pharma: Massive Opportunity Ahead
Nov 09Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21
Oct 14Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)
Oct 09Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt
Aug 28Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
Aug 22Royalty Pharma: Busy Putting Capital To Work
Aug 11Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21
Jul 22Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Royalty Pharma: Solid Start Of The Year, Buy Confirmed
May 11Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
Apr 28Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares
Apr 25Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Royalty Pharma: Solid Operational Performance
Feb 19Royalty Pharma: One Of The Best Names In Pharmaceuticals
Jan 22Financial Position Analysis
Short Term Liabilities: RPRX's short term assets ($1.8B) exceed its short term liabilities ($1.3B).
Long Term Liabilities: RPRX's short term assets ($1.8B) do not cover its long term liabilities ($6.6B).
Debt to Equity History and Analysis
Debt Level: RPRX's net debt to equity ratio (64.1%) is considered high.
Reducing Debt: RPRX's debt to equity ratio has reduced from 102% to 73.6% over the past 5 years.
Debt Coverage: RPRX's debt is well covered by operating cash flow (36.4%).
Interest Coverage: RPRX's interest payments on its debt are well covered by EBIT (7.3x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 16:20 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Royalty Pharma plc is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Jason Matthew Gerberry | BofA Global Research |
| Geoff Meacham | Citigroup Inc |